サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：遺伝子検査の世界市場：2022-2028年
市場調査レポート
商品コード
1123279

遺伝子検査の世界市場：2022-2028年

Global Genetic Testing Market Research and Forecast, 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 125 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
遺伝子検査の世界市場：2022-2028年
出版日: 2022年08月02日
発行: Orion Market Research
ページ情報: 英文 125 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の遺伝子検査の市場規模は予測期間中、大きなCAGRで成長しています。

同市場は、遺伝子疾患、癌、慢性疾患の蔓延により、今後大きく成長すると予測されています。遺伝子診断分野における医療企業の継続的な進歩も市場成長を後押ししています。また、人々の健康に対する意識の高まりや、世界の遺伝性疾患による死亡率の上昇も、遺伝子検査に対するニーズを高める大きな要因となっています。

当レポートでは、世界の遺伝子検査の市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 レポートの概要

第2章 市場概要・洞察

第3章 競合情勢

  • 企業シェア分析
  • 主要戦略分析
  • 主要企業分析

第4章 市場決定要因

  • 推進要因
  • 抑制要因
  • 機会

第5章 市場分析：区分別

  • 世界の遺伝子検査市場：技術別
    • PCR (ポリメラーゼ連鎖反応)
    • DNAシーケンシング
    • 細胞遺伝学（核型分析およびFISH）
    • マイクロアレイ
    • 遺伝子発現プロファイリング
  • 世界の遺伝子検査市場：タイプ別
    • 出生前および新生児遺伝子検査
    • 予測検査
    • 診断検査
    • キャリア検査
    • その他（法医学検査、着床前検査）
  • 世界の遺伝子検査市場：疾患別
    • 癌
    • アルツハイマー病およびパーキンソン病
    • 鎌状赤血球貧血
    • ファンコニ貧血
    • 循環器疾患
    • その他（嚢胞性線維症、デュシェンヌ型筋ジストロフィー）

第6章 地域分析

  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第7章 企業プロファイル

  • 23Andme, Inc.
  • Abbott Laboratories
  • AutoGenomics, Inc.
  • Biocartis SA
  • Biomerieux SA
  • Bio-Rad Laboratories, Inc.
  • Cepheid, Inc.
  • Elitech Group
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd.
  • Foundation Medicine, Inc.
  • Genomictree Inc.
  • Illumina, Inc.
  • Luminex Corp.
  • MedGenome, Inc.
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories, Inc.
  • Opko Health Inc.
  • PerkinElmer, Inc.
  • 7.19. Qiagen N.V.
  • 7.20. Quest Diagnostics, Inc.
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.
図表

LIST OF TABLES

1. GLOBAL GENETIC TESTING MARKET RESEARCH AND ANALYSIS, 2020-2027 ($MILLION)

2. GLOBAL GENETIC TESTING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2020-2027 ($MILLION)

3. GLOBAL POLYMERASE CHAIN REACTION MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($MILLION)

4. GLOBAL DNA SEQUENCING REACTION MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($MILLION)

5. GLOBAL CYTOGENETICS (KARYOTYPING AND FISH) MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($MILLION)

6. GLOBAL MICROARRAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($MILLION)

7. GLOBAL GENE EXPRESSION PROFILING MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($MILLION)

8. GLOBAL GENETIC TESTING MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($MILLION)

9. GLOBAL PRENATAL AND NEW-BORN GENETIC TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($MILLION)

10. GLOBAL PREDICTIVE TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($MILLION)

11. GLOBAL DIAGNOSTIC TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($MILLION)

12. GLOBAL CARRIER TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($MILLION)

13. GLOBAL OTHER GENETIC TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($MILLION)

14. GLOBAL GENETIC TESTING MARKET RESEARCH AND ANALYSIS BY DISEASE, 2020-2027 ($MILLION)

15. GLOBAL CANCER GENETIC TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027

16. GLOBAL ALZHEIMER'S AND PARKINSONSGENETIC TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027

17. GLOBAL FANCONI ANAEMIAGENETIC TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027

18. GLOBAL SICKLE CELL ANAEMIAGENETIC TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027

19. GLOBAL CARDIOVASCULAR DISEASE GENETIC TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027

20. GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027

21. NORTH AMERICAN GENETIC TESTING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($MILLION)

22. NORTH AMERICAN MARKET GENETIC TESTING RESEARCH AND ANALYSIS BY TECHNOLOGY, 2020-2027 ($MILLION)

23. NORTH AMERICAN GENETIC TESTING MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($MILLION)

24. NORTH AMERICAN GENETIC TESTING MARKET RESEARCH AND ANALYSIS BY DISEASE, 2020-2027 ($MILLION)

25. EUROPEAN GENETIC TESTING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($MILLION)

26. EUROPEAN GENETIC TESTING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2020-2027 ($MILLION)

27. EUROPEAN GENETIC TESTING MARKET RESEARCH AND ANALYSIS BY DISEASES, 2020-2027 ($MILLION)

28. EUROPEAN GENETIC TESTING MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($MILLION)

29. ASIA-PACIFIC GENETIC TESTING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($MILLION)

30. ASIA-PACIFIC GENETIC TESTING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2020-2027 ($MILLION)

31. ASIA-PACIFIC GENETIC TESTING MARKET RESEARCH AND ANALYSIS BY DISEASES, 2020-2027 ($MILLION)

32. ASIA-PACIFIC GENETIC TESTING MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($MILLION)

33. REST OF THE WORLD GENETIC TESTING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2020-2027 ($MILLION)

34. REST OF THE WORLD GENETIC TESTING MARKET RESEARCH AND ANALYSIS BY DISEASES, 2020-2027 ($MILLION)

35. REST OF THE WORLD GENETIC TESTING MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($MILLION)

LIST OF FIGURES

  • 1. GLOBAL GENETIC TESTING MARKET SHARE BY TECHNOLOGY, 2020 VS 2027 (%)
  • 2. GLOBAL GENETIC TESTING MARKET SHARE BY TYPE, 2020 VS 2027 (%)
  • 3. GLOBAL GENETIC TESTING MARKET SHARE BY DISEASE, 2020 VS 2027 (%)

4. GLOBAL GENETIC TESTING MARKET DEVICES MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%

  • 5. GLOBAL POLYMERASE CHAIN REACTION MARKET RESEARCH AND ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 6. GLOBAL DNA SEQUENCING MARKET RESEARCH AND ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 7. GLOBAL CYTOGENETICS (KARYOTYPING AND FISH) MARKET RESEARCH AND ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 8. GLOBAL MICROARRAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 9. GLOBAL GENE EXPRESSION PROFILING MARKET RESEARCH AND ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 10. GLOBAL PRENATAL AND NEW-BORN GENETIC TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 11. GLOBAL PREDICTIVE TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 12. GLOBAL DIAGNOSTIC TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 13. GLOBAL CARRIER TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 14. GLOBAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 15. GLOBAL ALZHEIMER'S AND PARKINSON'S MARKET RESEARCH AND ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 16. GLOBAL CARDIOVASCULAR DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 17. GLOBAL FANCONI ANAEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 18. GLOBAL SICKLE CELL ANAEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 19. GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 20. US GENETIC TESTING MARKET SIZE, 2020-2027 ($ MILLION)
  • 21. CANADA GENETIC TESTING MARKET SIZE, 2020-2027 ($ MILLION)
  • 22. UK GENETIC TESTING MARKET SIZE, 2020-2027 ($ MILLION)
  • 23. FRANCE GENETIC TESTING MARKET SIZE, 2020-2027 ($ MILLION)
  • 24. GERMANY GENETIC TESTING MARKET SIZE, 2020-2027 ($ MILLION)
  • 25. ITALY GENETIC TESTING MARKET SIZE, 2020-2027 ($ MILLION)
  • 26. SPAIN GENETIC TESTING MARKET SIZE, 2020-2027 ($ MILLION)
  • 27. REST OF EUROPE GENETIC TESTING MARKET SIZE, 2020-2027 ($ MILLION)
  • 28. INDIA GENETIC TESTING MARKET SIZE, 2020-2027 ($ MILLION)
  • 29. JAPAN GENETIC TESTING MARKET SIZE, 2020-2027 ($ MILLION)
  • 30. CHINA GENETIC TESTING MARKET SIZE, 2020-2027 ($ MILLION)
  • 31. REST OF ASIA PACIFIC GENETIC TESTING MARKET SIZE, 2020-2027 ($ MILLION)
  • 32. LATIN AMERICA GENETIC TESTING MARKET SIZE, 2020-2027 ($ MILLION)
  • 33. MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, 2020-2027 ($ MILLION)
目次
Product Code: OMR2018411

Global Genetic Testing Market Size, Share & Trends Analysis Report by technology (Polymerase Chain Reaction, DNA sequencing, Cytogenetics (Karyotyping and FISH), Microarrays, Gene Expression Profiling) By Type (Prenatal and New-Born Genetic Testing, Predictive Testing, Diagnostic Testing, Carrier Testing, and Other) By Diseases (Cancer, Alzheimer's and Parkinson, Fanconi Anaemia, Sickle Cell Anaemia, Cardiovascular Diseases, and Others), Forecast 2021-2027

The global genetic testing market is growing at a significant CAGR during the forecast period. The genetic disorder can be occurred by a change in one gene (monogenic disorder), by changes in multiple genes by a combination of environmental factors, and gene mutations, or by the destruction of chromosomes. Genetic testing is a medical test that is used for the identification of mutations in genes or chromosomes. The key benefit of genetic testing is the chance to know the risk for a certain disease that possibly can be prevented, identify the disease or a type of disease, identify the cause of a disease, to determine options for a disease. The disease that can be identified by genetic testing includes, breast and ovarian cancer, Age-Related Macular Degeneration (AMD), bipolar disorder, Parkinson's disease, celiac disease, and psoriasis.

The global genetic testing market is projected to considerably grow in the upcoming year due to the prevalence of genetic disorders, cancer, and chronic disease. Moreover, continuous advancement by the medical companies in the genetic diagnostic field is also augmenting the market growth. These companies are finding new and better tests for the accurate diagnosis of the most prevalent as well as rare diseases. Besides, the increase in awareness between people about health and the increased mortality rate due to genetic diseases across the globe is also a major factor increasing the need for demand for genetic testing.

Moreover, The adoption of (DTC) direct-to-consumer genetic testing kits in countries such as the US, China, and Japan, is increasing rapidly. With growing technological acceptances, awareness programs, and a drop in costs, the market for DTC-GT kits is likely to witness a significant boost over the forecast period. However, the lack of diagnostic infrastructure in emerging economies is a challenging factor for market growth.

Segmental Outlook

The global genetic testing market is segmented by technology, type, and disease. By technology, the market is segmented into polymerase chain reaction, DNA sequencing, cytogenetics (karyotyping and fish), microarrays, and gene expression profiling. By type, the market is divided into prenatal and newborn genetic testing, predictive testing, diagnostic testing, carrier testing, and others. Moreover, by disease type, the market is sub-segmented into cancer, Alzheimer's and Parkinson's, Fanconi anemia, sickle cell anemia, cardiovascular diseases, and others.

Global Genetic Testing Market Share by Disease, 2020 (%)

Global Genetic Testing Market Share by Disease

Based on disease type, cancer segment is expected to hold a major market share during the forecast period. The need for accurate testing for cancer at the early stages and prediagnostic testing are some of the major factors for the significant market share of the segment. It is since the number of the cancer patient are very high, government and companies are trying to increase the 5-year survival rate of fatal cancers. Genetic testing aids in estimate a person's chance of developing cancer in a lifetime. Genetic tests are available for some types of cancer. These include breast cancer, ovarian cancer, colon cancer, thyroid cancer, prostate cancer, pancreatic cancer, melanoma, sarcoma, kidney cancer, and stomach cancer.

Regional Outlooks

The global genetic testing market is analyzed on the basis of the geographical regions that are contributing significantly to the growth of the market. The market report covers the analysis of four major regions into North America, Europe, Asia-Pacific, and the Rest of the World. North America is estimated to contribute a significant share in the global genetic testing market due to the high awareness among the people about advanced treatment for healthcare, well-developed healthcare infrastructure, presence of key players, and availability of drugs. Moreover, an increase in government initiatives for the enhancement of healthcare facilities and funding in research in the region is also a major factor for the significant market share of the region. In the US under the US CDC EGAPP, inventiveness has been taken by the government such as the Evaluation of Genomic Applications in Practice and Prevention which is also motivating the market growth. One of the key goals of the initiative is to timely, offer objectively, and credible information that is linked to available scientific evidence. These statistics will allow healthcare workers and payers, customers, policymakers, and others to differentiate genetic tests that are safe and useful.

Global Genetic Testing Market Growth, by Region 2020-2026

Global Genetic Testing Market Growth, by Region

Asia-Pacific will have considerable growth in the global Genetic Testing Market

In Asia Pacific, the market is increasing due to government initiatives in research and the increasing prevalence of chronic diseases. Apart from cancer, genetic testing processes have also come in easy reach for the diagnosis of inherited cardiovascular diseases such as cardiac amyloidosis, Brugada syndrome, and familial dilated cardiomyopathy. As the region has a high incidence of cardiovascular diseases, significant scope for genetic testing can be witnessed in the region during the forecast period.

Market Players Outlook

The report covers the analysis of various players operating in the global genetic testing market. Some of the major players covered in the report include Abbott Laboratories, Myriad Genetics, Inc., F. Hoffmann-La Roche Ltd., Illumina, Inc., and Thermo Fisher Scientific, Inc. To survive in the market, these players adopt different marketing strategies such as mergers and acquisitions, product launches, and geographical expansion.

Recent Activity

In August 2020, Roche announced the US FDA clearance of FoundationOne Liquid CDx, it's a comprehensive pan-tumor liquid biopsy test, Liquid CDx analyses more than 300 cancer-related genes and multiple genomic signatures to benefit inform treatment decisions for all solid tumor cancers.

In May 2020, Myriad Genetics, Inc. announced the US FDA approval of my choice CDx for the treatment of patients having Advanced Ovarian Cancer. MyChoice CDx uses as a companion diagnostic to identify women with advanced ovarian cancer.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global female infertility diagnosis and treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Key Companyanalysis
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Key Strategy Analysis

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Genetic Testing Market by Technology
    • 5.1.1. Polymerase Chain Reaction
    • 5.1.2. DNA Sequencing
    • 5.1.3. Cytogenetics (Karyotyping and FISH)
    • 5.1.4. Microarrays
    • 5.1.5. Gene Expression Profiling
  • 5.2. Global Genetic Testing Market by Type
    • 5.2.1. Prenatal and New-Born Genetic Testing
    • 5.2.2. Predictive Testing
    • 5.2.3. Diagnostic Testing
    • 5.2.4. Carrier Testing
    • 5.2.5. Other (Forensic Testing, Pre-Implantation Testing)
  • 5.3. Global Genetic Testing Market by Disease
    • 5.3.1. Cancer
    • 5.3.2. Alzheimer's and Parkinson's
    • 5.3.3. Sickle Cell Anaemia
    • 5.3.4. Fanconi Anaemia
    • 5.3.5. Cardiovascular Disease
    • 5.3.6. Others (Cystic Fibrosis, Duchenne's Muscular Dystrophy)

6. Regional Analysis

  • 6.2. North America
    • 6.2.1. United States
    • 6.2.2. Canada
  • 6.3. Europe
    • 6.3.1. UK
    • 6.3.2. Germany
    • 6.3.3. Italy
    • 6.3.4. Spain
    • 6.3.5. France
    • 6.3.6. Rest of Europe
  • 6.4. Asia-Pacific
    • 6.4.1. China
    • 6.4.2. India
    • 6.4.3. Japan
    • 6.4.4. Rest of Asia-Pacific
  • 6.5. Rest of the World

7. Company Profiles

  • 7.1. 23Andme, Inc.
  • 7.2. Abbott Laboratories
  • 7.3. AutoGenomics, Inc.
  • 7.4. Biocartis SA
  • 7.5. Biomerieux SA
  • 7.6. Bio-Rad Laboratories, Inc.
  • 7.7. Cepheid, Inc.
  • 7.8. Elitech Group
  • 7.9. Eurofins Scientific SE
  • 7.10. F. Hoffmann-La Roche Ltd.
  • 7.11. Foundation Medicine, Inc.
  • 7.12. Genomictree Inc.
  • 7.13. Illumina, Inc.
  • 7.14. Luminex Corp.
  • 7.15. MedGenome, Inc.
  • 7.16. Myriad Genetics, Inc.
  • 7.17. NeoGenomics Laboratories, Inc.
  • 7.18. Opko Health Inc.
  • 7.19. PerkinElmer, Inc.
  • 7.20. 7.19. Qiagen N.V.
  • 7.21. 7.20. Quest Diagnostics, Inc.
  • 7.22. Takara Bio, Inc.
  • 7.23. Thermo Fisher Scientific, Inc.